Nightstar Therapeutics, a UK biotech developing gene therapies for rare retinal diseases, filed on Thursday with the SEC to raise up to $86 million in a US initial public offering.
The London, United Kingdom-based company was founded in 2013 and plans to list on the Nasdaq under the symbol NITE. Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
